Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.

abstract：:Overexpression of microRNA-99a (miR-99a) have been associated with adverse prognosis in acute myeloid leukemia (AML). Nevertheless, whether it also predicts poor outcome in post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) AML patients remains unclear. To further elucidate the prognostic value of miR...

journal_title：Bone marrow transplantation

authors： Cheng Z,Zhou L,Hu K,Dai Y,Pang Y,Zhao H,Wu S,Qin T,Han Y,Hu N,Chen L,Wang C,Zhang Y,Wu D,Ke X,Shi J,Fu L

更新日期：2018-09-01 00:00:00

abstract：:Toxoplasmosis in bone marrow transplant recipients is a rare but serious complication and if untreated, almost uniformly fatal. The diagnosis, however, remains difficult. We therefore compared serial determination of antibody titers specific for T. gondii before and after transplantation, serial PCR for T. gondii DNA ...

journal_title：Bone marrow transplantation

authors： Held TK,Krüger D,Switala AR,Beyer J,Kingreen D,Busemann C,Janitschke K,Siegert W

更新日期：2000-06-01 00:00:00

abstract：:Respiratory failure is the main cause of death in patients undergoing bone marrow transplantation (BMT). In this paper, clinical and research aspects as well as diagnostic, prophylactic and therapeutic strategies concerning the various forms of pulmonary and bronchial complications, which may evolve after BMT, are dis...

journal_title：Bone marrow transplantation

authors： Quabeck K

更新日期：1994-01-01 00:00:00

abstract：:Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

journal_title：Bone marrow transplantation

authors： Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

更新日期：1996-11-01 00:00:00

abstract：:This retrospective analysis was done to determine the response rate and survival of women with metastatic breast cancer with bone marrow involvement treated with high-dose cyclophosphamide and thiotepa and peripheral progenitor cell rescue. Eligibility criteria included histologically-documented metastatic breast canc...

journal_title：Bone marrow transplantation

authors： Myers SE,Mick R,Williams SF

更新日期：1994-04-01 00:00:00

abstract：:EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV...

journal_title：Bone marrow transplantation

authors： Sirvent-Von Bueltzingsloewen A,Morand P,Buisson M,Souillet G,Chambost H,Bosson JL,Bordigoni P

更新日期：2002-01-01 00:00:00

abstract：:We treated 12 patients with chronic myelogenous leukemia (CML) with a low-intensity preparative regimen followed by allogeneic stem cell transplantation in an attempt to confer a curative graft-versus-leukemia (GVL) effect with minimum morbidity. Seven patients in first chronic phase (CP1) and five in second chronic p...

journal_title：Bone marrow transplantation

authors： Sloand E,Childs RW,Solomon S,Greene A,Young NS,Barrett AJ

更新日期：2003-11-01 00:00:00

abstract：:The purpose of this work was to determine the maximum tolerated (phase II) dose of melphalan and etoposide that can be given in conjunction with autologous BM re-infusion in patients who have refractory or relapsed solid tumors. Twenty-six patients with refractory or relapsed breast cancer (n = 15), small cell lung ca...

journal_title：Bone marrow transplantation

authors： Lazarus HM,Gray R,Ciobanu N,Winter J,Weiner RS

更新日期：1994-09-01 00:00:00

abstract：:Allogeneic SCT for older patients remains challenging at least in part due to graft-versus-host disease (GVHD) and higher non-relapse mortality (NRM). We conducted a prospective pilot study primarily for older patients undergoing matched unrelated donor (MUD) SCT using a reduced-intensity (RIC) melphalan-based conditi...

journal_title：Bone marrow transplantation

authors： Shah MV,Saliba RM,Rondon G,Chen J,Soebbing D,Rus I,Alousi A,Oran B,Kebriaei P,Qazilbash M,Parmar S,Hosing C,Khouri IF,Popat UR,Champlin RE,Ciurea SO

更新日期：2019-04-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:Cyclosporin A (CsA) has been used clinically to induce graft-versus-host disease following autologous bone marrow transplantation in an attempt to destroy residual leukemia cells and reduce relapse. To analyze the antitumor potential of murine syngeneic graft-versus-host disease (SGVHD), C3H/HeN mice were lethally irr...

journal_title：Bone marrow transplantation

authors： Bryson JS,Jennings CD,Lowery DM,Carlson SL,Pflugh DL,Caywood BE,Kaplan AM

更新日期：1999-02-01 00:00:00

abstract：:Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

journal_title：Bone marrow transplantation

authors： Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

更新日期：2017-06-01 00:00:00

abstract：:CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160...

journal_title：Bone marrow transplantation

authors： Balasubramanian P,Desire S,Panetta JC,Lakshmi KM,Mathews V,George B,Viswabandya A,Chandy M,Krishnamoorthy R,Srivastava A

更新日期：2012-09-01 00:00:00

abstract：:Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been s...

journal_title：Bone marrow transplantation

authors： Yang H,Robinson SN,Lu J,Decker WK,Xing D,Steiner D,Parmar S,Shah N,Champlin RE,Munsell M,Leen A,Bollard C,Simmons PJ,Shpall EJ

更新日期：2010-06-01 00:00:00

abstract：:Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the...

journal_title：Bone marrow transplantation

authors： Liao Y,Cotten M,Tan S,Kurtzberg J,Cairo MS

更新日期：2013-07-01 00:00:00

abstract：:We report on 24 patients with leukemia (19 pts), congenital disorders (4 pts) or severe aplastic anemia (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions. All the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 ca...

journal_title：Bone marrow transplantation

authors： Lanino E,Lamparelli T,Dini G,Alessandrino EP,Aversa F,Calori E,Medugno D,Garbarino L,Locatelli F,Marenco P

更新日期：1993-01-01 00:00:00

abstract：:The presence of recipient disparity for a minor histocompatibility antigen termed HA-1 is associated with an increased risk of grades II-IV GVHD after marrow transplantation from an HLA-identical sibling. These data offer an opportunity to test the validity of theoretical models suggesting that the minor antigens capa...

journal_title：Bone marrow transplantation

authors： Martin PJ

更新日期：1997-07-01 00:00:00

abstract：:In comparison to bone marrow, umbilical cord blood has decreased intrinsic immune responsiveness allowing transplantation across HLA barriers with lower rates of graft-versus-host disease. However, laboratory models have also suggested that cord blood may be extremely sensitive to stimulation by cytokines. We report a...

journal_title：Bone marrow transplantation

authors： Goldberg SL,Pecora AL,Rosenbluth RJ,Jennis AA,Preti RA

更新日期：2000-08-01 00:00:00

abstract：:This article provides a brief overview of T cell tolerance induction in the thymus, using parent----F1 bone marrow (BM) chimeras as a model. Although intrathymic tolerance is controlled largely by BM-derived cells, experiments with BM chimeras suggest that thymic epithelial cells can make a major contribution to toler...

journal_title：Bone marrow transplantation

authors： Sprent J,Kosaka H,Gao EK

更新日期：1992-01-01 00:00:00

abstract：:Fourteen children with high risk leukaemia received allogeneic bone marrow transplants from HLA-identical MLC-compatible sibling donors. All bone marrows were T cell depleted and a T cell addback was prepared from the donor's peripheral blood so that the mean total number of CD3+ cells given was 2.6 (1.0-4.1) x 10(5)/...

journal_title：Bone marrow transplantation

authors： Potter MN,Pamphilon DH,Cornish JM,Oakhill A

更新日期：1991-11-01 00:00:00

abstract：:Salivary gland dysfunction is frequently observed in patients suffering from acute (a) and chronic (c) GVHD. We studied the influence of GVHD on the function of major salivary glands in 20 patients with GVHD (cGVHD, 15; aGVHD, 5). A subjective evaluation of salivary function was performed, in which the score ranged fr...

journal_title：Bone marrow transplantation

authors： Nagler R,Marmary Y,Krausz Y,Chisin R,Markitziu A,Nagler A

更新日期：1996-02-01 00:00:00

abstract：:Propylene Glycol-Free melphalan HCL for Injection (PGF-Mel) is a new formulation that incorporates Captisol, a specially modified cyclodextrin, to improve melphalan stability. In this phase IIa, open-label, randomized, cross-over design bioequivalence study, the pharmacokinetics of PGF-Mel were compared with the marke...

journal_title：Bone marrow transplantation

authors： Aljitawi OS,Ganguly S,Abhyankar SH,Ferree M,Marks R,Pipkin JD,McGuirk JP

更新日期：2014-08-01 00:00:00

abstract：:Allogeneic BMT is potentially curative for patients with acute myelogenous leukemia (AML) in first remission. However, many patients relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of patients at high risk for relaps...

journal_title：Bone marrow transplantation

authors： Kumar S,Chen MG,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Tefferi A,Litzow MR

更新日期：2001-11-01 00:00:00

abstract：:Microsporidia are obligate, intracellular protozoal parasites that can be pathogenic in immunocompromised individuals. The majority of cases of microsporidiosis have been documented in patients with HIV, and only a few case reports exist of infection in solid organ transplant patients. We report the first case of pulm...

journal_title：Bone marrow transplantation

authors： Teachey DT,Russo P,Orenstein JM,Didier ES,Bowers C,Bunin N

更新日期：2004-02-01 00:00:00

abstract：:Although allogeneic hematopoietic stem cell transplantation (HSCT) features severe physical and psychological strain, no previous study has prospectively investigated fatigue beyond 3 years after transplantation. We investigated the temporal course of fatigue over 5 years, compared patients with the general population...

journal_title：Bone marrow transplantation

authors： Esser P,Kuba K,Mehnert A,Schwinn A,Schirmer L,Schulz-Kindermann F,Kruse M,Koch U,Zander AR,Kröger N,Schilling G,Götze H,Scherwath A

更新日期：2017-05-01 00:00:00

abstract：:AlloSCT is a potentially curative procedure for haematological malignancies and marrow failure syndromes. However, unlike leukaemia and lymphoproliferative disorders, AlloSCT has yet to find its place in the clinical management of patients with multiple myeloma. AlloSCT in multiple myeloma is associated with a high pr...

journal_title：Bone marrow transplantation

authors： Cook G,Bird JM,Marks DI

更新日期：2009-01-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) was performed in 95 patients with chronic myelogenous leukemia (CML) in chronic phase and their data were reported to the European Bone Marrow Transplant Registry. Most patients presented bad prognostic factors. The results were analysed by September 1, 1993. The actuarial p...

journal_title：Bone marrow transplantation

authors： Reiffers J,Goldman J,Meloni G,Cahn JY,Faberes C,Apperley J

更新日期：1994-01-01 00:00:00

abstract：:Bone marrow transplantation was performed on an 8-month-old boy who was diagnosed as having fucosidosis following the diagnosis of the disease in his older brother. Although he was asymptomatic and his development was normal, abnomalities were found on an MRI scan prior to transplant. In the absence of a suitable rela...

journal_title：Bone marrow transplantation

authors： Vellodi A,Cragg H,Winchester B,Young E,Young J,Downie CJ,Hoare RD,Stocks R,Banerjee GK

更新日期：1995-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) ...

journal_title：Bone marrow transplantation

authors： Lawton CA,Cohen EP,Murray KJ,Derus SW,Casper JT,Drobyski WR,Horowitz MM,Moulder JE

更新日期：1997-12-01 00:00:00

abstract：:The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

journal_title：Bone marrow transplantation

authors： Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

更新日期：2014-02-01 00:00:00